4726 Stock Overview
Develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Mycenax Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$44.10 |
| 52 Week High | NT$65.20 |
| 52 Week Low | NT$34.90 |
| Beta | 1.08 |
| 1 Month Change | -2.65% |
| 3 Month Change | -6.17% |
| 1 Year Change | 24.58% |
| 3 Year Change | 17.29% |
| 5 Year Change | 89.27% |
| Change since IPO | 149.15% |
Recent News & Updates
Shareholder Returns
| 4726 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 3.8% | 2.0% | 0.4% |
| 1Y | 24.6% | 1.6% | 28.7% |
Return vs Industry: 4726 exceeded the TW Biotechs industry which returned 1.6% over the past year.
Return vs Market: 4726 underperformed the TW Market which returned 28.7% over the past year.
Price Volatility
| 4726 volatility | |
|---|---|
| 4726 Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4726 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4726's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 387 | Pei-Jiun Chen | www.mycenax.com.tw |
Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies.
Mycenax Biotech Inc. Fundamentals Summary
| 4726 fundamental statistics | |
|---|---|
| Market cap | NT$9.04b |
| Earnings (TTM) | -NT$536.33m |
| Revenue (TTM) | NT$672.85m |
13.5x
P/S Ratio-17.0x
P/E RatioIs 4726 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4726 income statement (TTM) | |
|---|---|
| Revenue | NT$672.85m |
| Cost of Revenue | NT$956.07m |
| Gross Profit | -NT$283.22m |
| Other Expenses | NT$253.11m |
| Earnings | -NT$536.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.60 |
| Gross Margin | -42.09% |
| Net Profit Margin | -79.71% |
| Debt/Equity Ratio | 38.4% |
How did 4726 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 12:30 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mycenax Biotech Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Regina Lee | Capital Securities Corporation |
| Li-chun Chang | Jih Sun Securities Investment Consulting Co., Ltd. |
| Hengyu Fu | Masterlink Securities Corp. |